Physician profile
Mohammad Atiq
NPI 1851719967
$794.52
in general payments reported to CMS, 2019-2025
13 companies · $419 in 2025
The $419 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $61.93 · 2023: $98.95 · 2024: $90.60 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $524 · Education: $83.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $524.28 |
| Education | $83.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $269.36 | 2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $134.98 | 2025 | |
| Janssen Biotech, INC. | $83.99 | 2023 | Rybrevant |
| W. L. Gore & Associates, INC. | $69.44 | 2024 | Gore Viabahn Vbx Balloon Expandable Endo |
| Pfizer INC. | $48.61 | 2019 | |
| Celgene Corporation | $37.71 | 2020 | |
| Fresenius USA Marketing, INC. | $29.34 | 2023-2025 | Velphoro, Velphoro |
| Rigel Pharmaceuticals, INC. | $24.22 | 2020 | |
| Astellas Pharma US INC | $21.69 | 2019 | |
| Bolton Medical INC | $21.16 | 2024 | Treo Abdominal Stent-Graft System |
| Jazz Pharmaceuticals INC. | $19.67 | 2019 | |
| Incyte Corporation | $18.93 | 2019 | |
| Agios Pharmaceuticals, INC. | $15.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Atiq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.